...
首页> 外文期刊>Asian Pacific Journal of Cancer Prevention >Comparison of Concurrent Chemoradiotherapy Followed by Adjuvant Chemotherapy Versus Concurrent Chemoradiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma: a Meta-analysis of 793 Patients from 5 Randomized Controlled Trials
【24h】

Comparison of Concurrent Chemoradiotherapy Followed by Adjuvant Chemotherapy Versus Concurrent Chemoradiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma: a Meta-analysis of 793 Patients from 5 Randomized Controlled Trials

机译:同时化疗疗法的比较随后由辅助化疗与单独的鼻咽癌鼻咽癌同时化疗:793例随机对照试验的793名患者的荟萃分析

获取原文
           

摘要

Purpose: The main objective of the present study was to evaluate the efficacy and toxicity of concurrent chemoradiotherapy followed by adjuvant chemotherapy compared with concurrent chemoradiotherapy alone in the treatment of locoregionally advanced nasopharyngeal carcinoma. Methods: The search strategy included Pubmed, Embase, the Cochrane Library, China National Knowledge Internet Web, Chinese Biomedical Database and Wanfang Database. We also searched reference lists of articles and the volumes of abstracts of scientific meetings. Randomized controlled trials (RCTs) that compared concurrent chemoradiotherapy followed by adjuvant chemotherapy with concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma were included. Meta-analysis was performed with RevMan 5.1.0. The Grading of Recommendations Assessment, Development, and Evaluation system (GRADE) was used to rate the level of evidence. Results: Five studies were included. Risk ratios of 1.02 (95%CI 0.89-1.15), 0.93 (95%CI 0.72-1.21), 1.07 (95%CI 0.87-1.32), 0.95 (95%CI 0.80-1.13) were observed for 3 years overall survival, 5 years failure-free survival, 5 years locoregional failure-free survival and 5 years distant metastasis failure-free survival. There were no treatment-related deaths in both groups of five studies. Hematologic and gastrointestinal toxicity were the most significant for patients during adjuvant chemotherapy. The level of evidence was low. Conclusion: Compared with concurrent chemoradiotherapy alone, concurrent chemotherapy followed by adjuvant chemotherapy did not improve prognosis. More toxicity was found during adjuvant chemotherapy.
机译:目的:本研究的主要目的是评估并发化疗的疗效和毒性,随后是佐剂化疗,与单独的化学疗法相比,单独的型鼻咽癌治疗。方法:搜索策略包括PubMed,Embase,Cochrane图书馆,中国全国知识互联网网络,中国生物医学数据库和万方数据库。我们还搜索了文章和科学会议摘要的参考列表。随机对照试验(RCT)将同时进行化学疗法,随后用同时进行化学疗法单独在型型鼻咽癌中进行佐剂化疗。使用Revman 5.1.0进行Meta分析。建议评估,发展和评估系统(等级)的评分用于评估证据水平。结果:包括五项研究。 1.02的风险比(95%CI 0.89-15),0.93(95%CI 0.72-1.21),1.07(95%CI 0.87-1.32),0.95(95%CI 0.8-1.13),整体存活3年, 5年无衰竭生存,5年招生无失败生存和5年远离转移失败的生存。五项研究中没有治疗有关的死亡。在佐剂化疗期间患者血液学和胃肠道毒性最重要。证据水平很低。结论:与单独的同步化学疗法相比,并发化疗随后进行佐剂化疗并未改善预后。在佐剂化疗期间发现了更多的毒性。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号